Repeat late instent-stenosis after an interval of four years in the same lesion after bare-metal and drug-eluting stent: a case report

Similar documents
Clinical Research Intracoronary Stenting with Crushing in Coronary Artery Bifurcation Lesions: Initial Results and Medium-Term Follow Up

Incidence of stent thrombosis and adverse cardiac events 5 years after sirolimus stent implantation in clinical practice

Intracoronary Stenting and. Robert A. Byrne, Julinda Mehilli, Salvatore Cassese, Franz-Josef Neumann, Susanne Pinieck, Tomohisa Tada,

Incidence and Correlates of Drug-Eluting Stent Thrombosis in Routine Clinical Practice

Duration of Dual Antiplatelet Therapy After Coronary Stenting

Drug-Eluting Balloons. Klaus Bonaventura Department of Cardiology and Angiology Heart Thorax Vascular Center, Klinikum Ernst von Bergmann, Potsdam

Why the provisional single-stent approach is not always the right strategy; arguments for the development of dedicated bifurcation devices

Status of Drug-Eluting Coronary Stents

Prognostic impact of uric acid in patients with stable coronary artery disease

Repeat Coronary Revascularization Procedures after Successful Bare-Metal or Drug-Eluting Stent Implantation

Interventional Cardiology

Antonio Colombo MD on behalf of the SECURITY Investigators

Impact of Drug-Eluting Stents Among Insulin-Treated Diabetic Patients

Department of the Heart and Great Vessels Attilio Reale, Sapienza University, Rome, Italy

Review Article CORONARY STENTS - PAST, PRESENT AND FUTURE.

Clinical Results of Unprotected Left Main Coronary Stenting

Clinical research. KEYWORDS Paclitaxel eluting stent, unprotected left main coronary artery, percutaneous coronary intervention, multicentre registry

Cilostazol versus Clopidogrel after Coronary Stenting

ORIGINAL ARTICLES: Morphology and Location of Restenosis Following Bare Metal Coronary Stenting

High incidence of thrombus formation at 18 months after paclitaxel-eluting stent implantation: Angioscopic comparison with sirolimus-eluting stent

Controversies in the use & implementation of drug-eluting stent technology

Is Stenting or Coronary Artery By-pass Grafting the Better Treatment for This Patient?

MEDICAL POLICY No R1 DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE

Will Stents of New Technology Replace Coronary Artery Bypass Surgery?

None. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015

Abstract. J Teh Univ Heart Ctr 2012;7(2):47-52

The optimal treatment of multivessel coronary artery disease

prodigy study: duration of dual antiplatelet therapy under review In BrIef In Brief NPS RADAR AuguSt 2012

Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto

Optimal Duration of Dual Antiplatelet Therapy

PRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators

LEADERS: 5-Year Follow-up

WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION. Van Crisco, MD, FACC, FSCAI First Coast

Ostial LAD: Single stent approach is the best. Antonio A. Pocoví, MD, FSCAI, MTSAC, Advisory Council Member, CACI

JUL Ms. Kendra Basler Regulatory Affairs Associate Abbott Vascular Cardiac Therapies 3200 Lakeside Drive Santa Clara, CA

Validation of a Risk Score for Target Vessel Revascularization after Coronary Stent Implantation

The infamous coronary stent saga

POST STENTING DUAL ANTIPLATELET THERAPY DURATION J BAUCUM MD FACC CAROLINA CARDIOLOGY GHS

Presenter: Marco Valgimigli, MD PhD, FESC Erasmus MC, Thoraxcenter Rotterdam The Netherlands

A Patient s Guide to Primary and Secondary Prevention of Cardiovascular Disease Using Blood-Thinning (Anticoagulant) Drugs

Understanding Coronary Artery Disease, Cardiac Catheterization, and Treatment Options. A Guide for Patients

The Anti coagulated Patient: The Cardiologist s View. February 28, 2015

Coronary Bifurcation Treatment: Update from the European Bifurcation Club. Remo Albiero, MD Ist. Clinico S. Rocco Brescia (Italy)

9/5/14. Objectives. Atrial Fibrillation (AF)

Dual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute

University of Ulsan College of Medicine, Asan Medical Center on behalf of the REAL-LATE and the ZEST-LATE trial

Main Effect of Screening for Coronary Artery Disease Using CT

The Bioresorbable Vascular Stent Dr Albert Ko

SCORM. For more patient education, please visit

Pooled RESOLUTE Clinical Program

The author has no disclosures

THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT

Early healing after treatment of coronary lesions by everolimus, or biolimus eluting bioresorbable polymer stents

Is There A LIfe for DES after discontinuation of Clopidogrel

Triple thérapie anti-thrombotique chez le coronarien. Y Cottin Dijon

Editorial. Adult Cardiology - Meta-analysis

OCT ASSESSMENT OF CUTTING BALLOON ANGIOPLASTY FOR IN-STENT RESTENOSIS

The Pantera Lux Paclitaxel DEB Device Description and Clinical Studies. Christoph Hehrlein, University Clinic Freiburg i.br.

DATE: 29 August 2012 CONTEXT AND POLICY ISSUES

Aaron M. From 1, MD; Firas J. Al Badarin 1, MBBS; Stephen S. Cha 2, MS; Charanjit S. Rihal 1 *, MD, FACC

Coronary-Artery Stents

GENERAL HEART DISEASE KNOW THE FACTS

Drug Eluting Stent Implantation for High Risk Patients and. Novel Technologies in Percutaneous Coronary Intervention

Getting smart about dyspnea and life saving drug therapy in ACS patients. Kobi George Kaplan Medical Center Rehovot

European Heart Journal (1999) 20, Article No. euhj , available online at on

Drug-Eluding Stents as an Alternative to Traditional Stenting in the Treatment of Coronary Artery Disease

Using Clinical Registries to Create Evidence-based Health Care Policy : Experiences from Ontario, Canada

EXAMINATION trial. Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators)

Polymer-Based, Paclitaxel-Eluting TAXUS Liberté Stent in De Novo Lesions: The Pivotal TAXUS ATLAS Trial

The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November :38

Copenhagen University Hospital Rigshospitalet Aarhus University Hospital Skejby Denmark

Investor News. Not intended for U.S. and UK media

Benefits and Risks of Extended Dual Antiplatelet Therapy after Everolimus-Eluting Stents

Rivaroxaban for acute coronary syndromes

MANAGEMENT AKUTES KORONARSYNDROM: RISIKOSTRATIFIZIERUNG UND THERAPIE. Peter Wenaweser Universitätsklinik für Kardiologie

INTRODUCTION. Key Words:

EMA Reaffirms Positive Benefit-Risk Balance of Bayer s Xarelto for Stroke Prevention in Patients with Atrial Fibrillation

In this observational study, the effect of dabigatran and rivaroxaban on platelets will be evaluated.

STROKE PREVENTION IN ATRIAL FIBRILLATION

Clopidogrel and long-term outcomes after stent implantation for acute coronary syndrome

California Health and Safety Code, Section

Should EDTA Chelation Therapy be Used Instead of Long-term Clopidogrel plus Aspirin to Treat Patients at Risk from Drug-Eluting Stents?

Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease

Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention

The Minvasys Amazonia Pax & Nile Pax Polymer Free Paclitaxel Eluting Stent Program

Hot Line Session at European Society of Cardiology (ESC) Congress 2014:

Cardiovascular disease has become a dominant cause of

Antiplatelet and Antithrombotics From clinical trials to guidelines

Interventional Cardiology

CARDIAC RISKS OF NON CARDIAC SURGERY

DUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania

Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg

Bayer Pharma AG Berlin Germany Tel News Release. Not intended for U.S. and UK Media

Preoperative Cardiac Stents Perioperative Management. Mark A. Taylor, MD Department of Anesthesia

Translating clinical evidence into real-world outcomes

Antiaggreganti. STEMI : cosa c è di nuovo? Heartline Genova Novembre 2015

A Patient Information Guide for the CYPHER Sirolimus-eluting Coronary Stent

Perioperative Management of Patients With Coronary Stents

Abstract. n engl j med 360;3 nejm.org january 15,

MISSING DATA ANALYSIS AMONG PATIENTS IN THE PINNACLE REGISTRY

Transcription:

Repeat late instent-stenosis after an interval of four years in the same lesion after bare-metal and drug-eluting stent: a case report Frank Towae*, Ralf Zahn, and Uwe Zeymer Address: Department of Cardiology Herzzentrum Ludwigshafen, Medizinische Klinik B, 67063 Ludwigshafen, Germany Email addresses FT*: frank@towae.com RZ: zahnr@klilu.de UZ: zeymeru@klilu.de Corresponding author* Received: 28 May 2009 Accepted: 19 September 2009

Abstract In 2001, a 71-year-old male was admitted to our hospital with unstable angina. The angiography revealed 2-vessel disease with a 90 % stenosis of the proximal LAD. A baremetal stent was implanted. Four years later the angiography showed a 80 % instentstenosis in the bare-metal stent but no progress at the other coronary arteries. A DES was implanted. Again, four years later, the patient presented with non-st-elevation myocardial infarction. Angiography showed a 90% instent-restenosis, again without any progession of coronary artery disease in the other vessels.again a DES implanted. Therefore the processes involved in the late instent-stenosis were not influenced by the antiproliferative agent sirolimus Case presentation In April 2001 a 71-year old male (German) was admitted to our hospital with unstable angina. Blood pressure at admission was 160/80 mmhg, LDL cholesterol was 127 mg/dl and no diabetes exist. The electrocardiogram showed persistent atrial fibrillation with negative T-waves in leads V 2 -V 5. The angiography revealed 2-vessel disease with a 90 % stenosis of the proximal LAD (Figure 1a). A bare-metal stent (3.0/18mm) was implanted (Figure 1b). Aspirin und clopidogrel were prescribed against stent-thrombosis by the use of bare-metal stent for 4 weeks followed by oral anticoagulation with a vitamin-k antagonist (INR 2-3, phenprocoumon). Four years later the same patient was hospitalized once again with stable angina. Blood pressure was 130/70 mmhg at admission and in the meanwhile the patient had diabetes. The angiography showed a 80 % instent-stenosis in the bare-metal stent but no progress at the other coronary arteries (Figure 2a). This time a sirolimus-eluting stent (CYPHER 3.0/23 mm) was implanted (Figure 2b). Aspirin, clopidogrel and the same oral anticoagulation (phenprocoumon) were given for three months against stent-thrombosis by use of drug-eluting stent followed by oral anticoagulation alone. Again, four years later, in February 2009, the patient presented with non-st-elevation myocardial infarction. Blood pressure was 120/80 mmhg at admission and the patient presented with the same risk factors as prescribed. Angiography showed a 90% instent-restenosis in the LAD again without any progression of coronary artery disease in the other vessels (Figure 3a). Again, a drugeluting stent (XIENCE V 3.0/28mm) implanted (Figure 3b). Discussion This case is unusual, because a late instent-stenosis was observed twice without any difference in the time interval of the clinical occurrence of the restenosis between baremetal and drug-eluting stent. Usually restenosis occurs within 6 months after stent implantation. Thereafter the annual restenosis rate is only about 1-2%. In this case, the implantation of a DES did not prolong the time-interval until the restenosis became

clinically apparent. Therefore, the processes involved in the late instent-stenosis in this patient were not influenced by the antiproliferative agent sirolimus. Consent Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal. Competing interests The authors declare that they have no competing interests. Authors contributions FT: Collected the data and wrote the case report, RZ, Reviewed the report and give suggestions, UZ: Reviewed the report and give suggestions. References 1. Chieffo A, Park SJ, Meliga E, Sheiban I, Lee MS, Latib A, Kim YH, Valgimigli M, Sillano D, Magni V, Zoccai GB, Montorfano M, Airoldi F, Rogacka R, Carlino M, Michev I, Lee CW, Hong MK, Park SW, Moretti C, Bonizzoni E, Sangiorgi GM, Tobis J, Serruys PW, Colombo A: Late and very late stent thrombosis following drug-eluting stent implantation in unprotected left main coronary artery: a multicentre registry. Eur Heart J 2008, 29(17):2108-2115. 2. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW: A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007, 356:989 997. 3. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Juni P, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PW: Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007, 369:667 678. 4. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, Menichelli M, Sabate M, Suttorp MJ, Baumgart D, Seyfarth M, Pfisterer ME, Schomig A: Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007, 356:1030 1039. 5. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MB: Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007, 356:998 1008.

Figures legends Figure 1. (a) Initial angiography with a high grade stenosis of the proximal LAD. (b) Angiography after implantation of a bare-metal stent. Figure 2. (a) First instent stenosis in 2005. (b). Result after PCI with a drug-eluting stent. Figure 3. (a) Second instent-stenosis in 2009. (b) Final result after PCI with drugeluting stent in 2009

Figure 1

Figure 2